Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus versus tacrolimus + mycophenolate in maintenance kidney transplant recipients for cardiovascular profile improvement
2009-013780-19Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2010
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial comparing Everolimus + mycophenolate mofetil with Tacrolimus + mycophenolate mofetil (2 arms). Primary endpoints: Degree of left ventricular hypertrophy at 24 months and Intermediate assessment of left ventricular hypertrophy at 12 months. Started Jan 2010; status: completed.
02
Drugs
everolimustacrolimusmycophenolate mofetil
Beyond the preview
Go deeper on 2009-013780-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013780-19.